SAN FRANCISCO — Use of IV tranexamic acid during tibial tubercle osteotomy did not significantly impact blood loss or hemarthrosis, opioid consumption, postoperative pain or functional outcomes, according to results presented here. Michael J. Alaia, MD, and colleagues categorized patients undergoing tibial tubercle osteotomy into groups to receive either 1 g of IV tranexamic acid